Molecule
Hydrocortisone is a corticosteroid indicated in conditions. It is available as cream, tablets and ointment for topical, oral and intramuscular use. MedsAcross supplies Hydrocortisone for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
Hydrocortisone tablets are indicated in the following conditions. 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice, synthetic analogs may be used in conjunction with mineralocorticoids where applicable, in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Non suppurative thyroiditis Hypercalcemia associated with cancer 2.
Source: US FDA prescribing information
ACTIONS Naturally occurring glucocorticoids (hydrocortisone and cortisone), which also have salt-retaining properties, are used as replacement therapy in adrenocortical deficiency states. Their synthetic analogs are primarily used for their potent anti-inflammatory effects in disorders of many organ systems. Glucocorticoids cause profound and varied metabolic effects. In addition, they modify the body’s immune responses to diverse stimuli.
Source: US FDA prescribing information
The initial dosage of hydrocortisone tablets may vary from 20 mg to 240 mg of hydrocortisone per day depending on the specific disease entity being treated. In situations of less severity lower doses will generally suffice while in selected patients higher initial doses may be required. The initial dosage should be maintained or adjusted until a satisfactory response is noted. If after a reasonable period of time there is a lack of satisfactory clinical response, hydrocortisone should be discontinued and the patient transferred to other appropriate therapy. IT SHOULD BE EMPHASIZED THAT DOSAGE REQUIREMENTS ARE VARIABLE AND MUST BE INDIVIDUALIZED ON THE BASIS OF THE DISEASE UNDER TREATMENT AND THE RESPONSE OF THE PATIENT.
Source: US FDA prescribing information
Systemic fungal infections and known hypersensitivity to components
Source: US FDA prescribing information
In patients on corticosteroid therapy subjected to unusual stress, increased dosage of rapidly acting corticosteroids before, during, and after the stressful situation is indicated. Immunosuppression and Increased Risk of Infection Corticosteroids, including CORTEF, suppress the immune system and increase the risk of infection with any pathogen, including viral, bacterial, fungal, protozoan, or helminthic pathogens. Corticosteroids can: • Reduce resistance to new infections • Exacerbate existing infections • Increase the risk of disseminated infections • Increase the risk of reactivation or exacerbation of latent infections • Mask some signs of infection Corticosteroid-associated infections can be mild but can be severe and at times fatal. The rate of infectious complications increases with increasing corticosteroid dosages.
Source: US FDA prescribing information
Fluid and Electrolyte Disturbances Sodium retention Fluid retention Congestive heart failure in susceptible patients Potassium loss Hypokalemic alkalosis Hypertension Musculoskeletal Muscle weakness Steroid myopathy Loss of muscle mass Osteoporosis Tendon rupture, particularly of the Achilles tendon Vertebral compression fractures Aseptic necrosis of femoral and humeral heads Pathologic fracture of long bones Gastrointestinal Peptic ulcer with possible perforation and hemorrhage Pancreatitis Abdominal distention Ulcerative esophagitis Increases in alanine transaminase (ALT, SGPT), aspartate transaminase (AST, SGOT) and alkaline phosphatase have been observed following corticosteroid treatment. These changes are usually small, not associated with any clinical syndrome and are reversible upon discontinuation.
Source: US FDA prescribing information
The pharmacokinetic interactions listed below are potentially clinically important. Drugs that induce hepatic enzymes such as phenobarbital, phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response. Drugs such as troleandomycin and ketoconazole may inhibit the metabolism of corticosteroids and thus decrease their clearance. Therefore, the dose of corticosteroid should be titrated to avoid steroid toxicity. Corticosteroids may increase the clearance of chronic high dose aspirin. This could lead to decreased salicylate serum levels or increase the risk of salicylate toxicity when corticosteroid is withdrawn. Aspirin should be used cautiously in conjunction with corticosteroids in patients suffering from hypoprothrombinemia. The effect of corticosteroids on oral anticoagulants is variable.
Source: US FDA prescribing information
Store at controlled room temperature 20° to 25°C (68° to 77°F).
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
37 presentations of Hydrocortisone, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Hydrocortisone 2.5% creamTopicalGeneric name | — | US FDA | Available on request |
| Hydrocortisone 5 mg tabletOralGeneric name | — | US FDA | Available on request |
| Hydrocortisone 10 mg tabletOralGeneric name | — | US FDA | Available on request |
| Hydrocortisone 20 mg tabletOralGeneric name | — | US FDA | Available on request |
| Hydrocortisone 2.5% ointmentTopicalGeneric name | — | US FDA | Available on request |
| Hydrocortisone 1% creamTopicalGeneric name | — | US FDA | Available on request |
| Hydrocortisone 25 mg/mL lotionTopicalGeneric name | — | US FDA | Available on request |
| Proctozone-hc 2.5% creamTopical | Rising Pharma Holdings | US FDA | Available on request |
| Solu-Cortef 100 mg/2 mL powder for injectionIntramuscular, intravenous | Pharmacia & Upjohn | US FDA | Available on request |
| Procto-Med HC 2.5% creamTopical | Leading Pharma | US FDA | Available on request |
| Hydrocortisone 100 mg/2 mL powder for injectionIntramuscular, intravenousGeneric name | — | US FDA | Available on request |
| Hydrocortisone 100 mg/2 mL injectionIntramuscular, intravenousGeneric name | — | US FDA | Available on request |
| Solu-Cortef 1000 mg/8 mL powder for injectionIntramuscular, intravenous | Pharmacia & Upjohn | US FDA | Available on request |
| Alacort 2.5% creamTopical | Crown Laboratories | US FDA | Available on request |
| Hydrocortisone 2% creamTopicalGeneric name | — | US FDA | Available on request |
| Hydrocortisone Rectal Suspension (Retention) 100 mg/60 mL rectal suspensionRectal | Chartwell RX | US FDA | Available on request |
| Proctosol-HC 2.5% creamTopical | Sun Pharmaceutical IndustriesIndia | US FDA | Available on request |
| Ala-Scalp 20 mg/mL lotionTopical | Derm Ventures | US FDA | Available on request |
| Alacort 1% creamTopical | Crown Laboratories | US FDA | Available on request |
| Cortenema 100 mg/60 mL enemaRectal | ANI Pharmaceuticals | US FDA | Available on request |
| Hydrocortisone 1% ointmentTopicalGeneric name | — | US FDA | Available on request |
| Hydrocortisone 100 mg/60 mL rectal suspensionRectalGeneric name | — | US FDA | Available on request |
| Hydrocortisone 20 mg/mL lotionTopicalGeneric name | — | US FDA | Available on request |
| Alkindi Sprinkle 0.5 mg granulesOral | Eton Pharmaceuticals | US FDA | Available on request |
| Alkindi Sprinkle 1 mg granulesOral | Eton Pharmaceuticals | US FDA | Available on request |
| Alkindi Sprinkle 2 mg granulesOral | Eton Pharmaceuticals | US FDA | Available on request |
| Alkindi Sprinkle 5 mg granulesOral | Eton Pharmaceuticals | US FDA | Available on request |
| Anusol HC 2.5% creamTopical | Salix Pharmaceuticals | US FDA | Available on request |
| Cortef 10 mg tabletOral | Pharmacia & Upjohn | US FDA | Available on request |
| Cortef 20 mg tabletOral | Pharmacia & Upjohn | US FDA | Available on request |
| Cortef 5 mg tabletOral | Pharmacia & Upjohn | US FDA | Available on request |
| Cortifoam 10% foamTopical | Viatris Specialty | US FDA | Available on request |
| Hydrocortisone 100 mg/60 mL enemaRectalGeneric name | — | US FDA | Available on request |
| Hydrocortisone 25 mg/mL topical solutionTopicalGeneric name | — | US FDA | Available on request |
| Hydrocortisone 250 mg/2 mL powder for injectionIntramuscular, intravenousGeneric name | — | US FDA | Available on request |
| Khindivi 1 mg/mL oral solutionOral | Eton Pharmaceuticals | US FDA | Available on request |
| Texacort 25 mg/mL topical solutionTopical | Mission Pharmacal | US FDA | Available on request |
14 brand names across 1 markets.
Indian manufacturers are highlighted.
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
Conditions linked to Hydrocortisone in public data. This is not a list of approved uses, see the clinical information.
Yes, on request. MedsAcross lists 37 presentations of Hydrocortisone and sources them for licensed hospitals, importers and physicians against valid import documents. Indian manufacturers include Sun Pharmaceutical Industries.
The catalogue lists 14 brand names for Hydrocortisone, including Ala-Scalp, Alacort, Alkindi Sprinkle, Anusol HC, Cortef, Cortenema, Cortifoam, Hydrocortisone Rectal Suspension (Retention).
Yes. The US FDA first approved Hydrocortisone on 21 December 1951, according to Drugs@FDA.
Yes. Hydrocortisone has a central EU marketing authorisation (status: authorised), according to European Medicines Agency data.
No listed presentation of Hydrocortisone is recorded as needing a cold chain. Storage conditions are shown on each presentation page.
Hydrocortisone is classified under ATC code A01AC03 (Hydrocortisone).
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.